/clinical/,/clinical/tools-resources/,/clinical/tools-resources/lab-test-directory/,/clinical/tools-resources/lab-test-directory/chemistry/,

/clinical/tools-resources/lab-test-directory/chemistry/name-67724-en.labtest

Feb 8, 2018

page

100

UWHC,UWMF,

Clinical Hub,Tools & Resources,UWHC Lab Test Directory,Chemistry

PSA Total, Screen

PSA Total, Screen (PSAM) Chemistry Lab Test

Name: PSA Total, Screen

Test Name: PSA Total, Screen

Health Link Test Code: PSAM

LIS Test Code: PSAS

CPT Code(s): G0103

Methodology: Chemiluminescent Immunoassay

Days Performed: Daily, 24 hours.

In-Lab Turnaround Time: 4 hours.

Stat In-Lab Turnaround Time: 1 hour.

Specimen: Blood

Collection Container: Red cap with yellow ring (SST)

Also Acceptable: Red top

Collection Volume: 2 mL

Pediatric Collection Volume: 0.3 mL

Stability Refridgerated:

24 hours

Stability Frozen:

>24 hours

Sample Analyzed: Serum

Testing Volume: 1 mL

Pediatric Testing Volume: 0.15 mL

Specimen Processing:

Centrifuge. If a complete barrier has not formed, transfer cell-free serum to plastic vial. Refrigerate.

Specimen Transport:

Transport entire specimen to the laboratory. Transport with coolant pack if coming from clinic location. Send frozen if sample will be more than 24 hours old when it arrives.

Interpretation:

 18 years and up:  0.00-4.00 ng/mL

Interpretation Type: Reference Interval

Test Limitations:

Testing performed on Abbott Architect i2000.

 

Samples should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA levels persisting for up to 3 weeks.

 

Studies have shown conflicting results on the existence of an effect of digital rectal examination on PSA level. Therefore, when possible, obtain PSA samples before digital rectal examination.

 

PSA expression may be altered due to hormonal therapy for prostate cancer. Consequently, a low PSA result following a prostatic cancer treatment which includes hormonal therapy may not adequately reflect the presence of residual or recurrent disease.

 

Results may be affected if patient has developed Human Anti-Murine Antibodies (HAMA) due to exposure to murine based products.

 

Heterophilic antibodies in human serum can react with the immunoglobulins included in the assay components causing interference with in vitro immunoassays. Samples from patients routinely exposed to animals or animal serum products can demonstrate this type of interference potentially causing an anomalous result.

 

A high dose hook effect is not seen up to 48,000 ng/mL.

Additional Information:

The PSA assay may be used in conjunction with a digital rectal exam as a screening test for prostate cancer.